Get all premium features to the best stock analysis tool

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena partners presented clinical data updates for prasinezumab for Parkinson's and BMS-986446 for Alzheimer's disease at AD/PD™ 2026.

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena earned a $50 million milestone from Novo Nordisk related to enrollment in the Phase 3 CLEOPATTRA trial evaluating coramitug for ATTR-CM.

Prothena Announces up to $100 Million Share Repurchase Plan

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced its Board has authorized a Share Repurchase Plan so it may repurchase up to $100 million of the Company's outstanding shares.

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights.